KEY TAKEAWAYSModerna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.Moderna expects to become self-funding by 2028, head of investor relations Lavina Talukdar said at the Jefferies London Healthcare Conference.Moderna stock is down almost 60% this year, however, and—like other vaccine makers—was hit recently by President-elect Donald Trump's nomination of vaccine sceptic Robert F. Kennedy Jr. ...

Moderna, Inc. (NASDAQ:MRNA) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session. This afternoon, we have the pleasure of having Moderna here with us and up on the front is the Head of Investor Relations, who everybody knows, Lavina Talukdar. Thank you for joining us. I would say quite a timely discussion because there ...

Moderna, Inc. (NASDAQ:MRNA) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session. This afternoon, we have the pleasure of having Moderna here with us and up on the front is the Head of Investor Relations, who everybody knows, Lavina Talukdar. Thank you for joining us. I would say quite a timely discussion because there ...

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services.Including Moderna Inc MRNA, several stocks witnessed a decline as Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism.Goldman Sachs hosted an investor lunch with Moderna CEO Stéphane Bancel, President Stephen Hoge, and Lavina Talukdar, S ...

Moderna, Inc. (NASDAQ:MRNA) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Evan Wang - Guggenheim Securities Evan Wang [Call Starts Abruptly] Inaugural Health Innovation Conference. I'm Evan Wang, one of the senior biotech analysts at Guggenheim. I'm joined by Stephen Hoge, who is Moderna's President, Head of R&D and now Head of Commercial. I appreciate you being here, Stephen. I'm glad you've a ...

ToplineStocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select vaccine skeptic Robert F. Kennedy Jr. as the head of the Department of Health and Human Services.Trump announced his pick Thursday afternoon. (Photo by Tom Brenner for The Washington Post via Getty ... [+] Images)The Washington Post via Getty Images Key FactsTrump confirmed his selection of RFK Jr. on Thur ...

Moderna, Inc. (NASDAQ:MRNA) UBS Global Healthcare Conference November 13, 2024 6:30 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Eliana Merle Good afternoon, everyone. Thank you for joining us at the UBS Healthcare Conference. I'm Eliana Merle. I'm one of the biotech analysts here at UBS. Very happy to have Moderna here with us today for fireside chat. Joining us from Moderna is Jamey Mock, Chief Financial Officer. Jamey, thank you so much f ...

On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.BofA Securities notes that Moderna’s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company’s respiratory vaccine lineup, as well as new concerns related to Trump and Kennedy’s positions on vacci ...

Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.The reported revenue represents a surprise of +47.73% over the Zacks Consensus Estimate of $1.26 billion. With the consensus EPS estimate being -$1.89, the EPS surprise was +101.59%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdicti ...